



## Teleflex announces Restated Indications for Use for EZ-IO® Vascular Access System

March 17, 2014

*Restated Indications for Use modify the weight range for the EZ-IO® 25 mm Needle Set for patients 3 kg or over*

WAYNE, Pa.--(BUSINESS WIRE)--Mar. 17, 2014-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, has announced FDA 510(k) clearance for restated Indications for Use of the EZ-IO® Vascular Access System. The EZ-IO® 25 mm Needle Set is now indicated for patients 3 kg or over. Teleflex recently announced its acquisition of Vidacare Corporation, developer of the EZ-IO® Vascular Access System. Vidacare is a leading provider of intraosseous (IO), or inside the bone access devices.

"In my clinical work in a free-standing, academic pediatric emergency department and level 1 trauma center, as well as in a large community hospital emergency department, rapid identification and treatment of serious conditions is paramount," states Mark L. Waltzman, MD, FAAP, Chief of Pediatrics, South Shore Hospital, Assistant Professor, Department of Pediatrics at Harvard Medical School and affiliation with the Division of Emergency Medicine at Boston Children's Hospital. Dr. Waltzman is also a paid consultant for Teleflex. "The restated indication for the EZ-IO® 25 mm Needle Set to be used in patients 3 kg or over will help to avoid confusion and streamline care. Clinicians now will simply assess the tissue depth and choose the correct needle size. This is something we 'in the trenches' clinicians have requested from the company and I am gratified they have heard our feedback and pushed for this change."

New weight ranges for the EZ-IO® Vascular Access System are now as follows:

<b>Description:</b>	<b>Weight Classification</b>
EZ-IO® 45 mm Needle	40 kg or over
EZ-IO® 25 mm Needle	3 kg or over
EZ-IO® 15 mm Needle	3 – 39 kg

"As part of our fight for zero complications in vascular access, we are committed to continuously improving our technologies, enhancing our training and educational initiatives, and partnering with healthcare professionals to provide innovative solutions for treating difficult vascular access patients with the EZ-IO® Vascular Access System," states Jay White, President and General Manager, Vascular Access Division, Teleflex. "We're excited about the restated Indications for Use, because we've made it even easier for clinicians to select the right needle for their patient."

### **About Teleflex Incorporated**

Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Wayne, PA, Teleflex employs approximately 11,400 people worldwide and serves healthcare providers in more than 150 countries. Additional information about Teleflex can be obtained from the company's website at [teleflex.com](http://teleflex.com).

### **Forward-Looking Statements**

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

*Teleflex and EZ-IO are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.*

*© 2014 Teleflex Incorporated. All rights reserved. 2014-2900*

Source: Teleflex Incorporated

Teleflex Incorporated  
Jake Elguicze  
Treasurer and Vice President, Investor Relations  
610-948-2836